Bridges Investment Management Lifted By $1.66 Million Its Gilead Sciences (GILD) Position; 1 Analysts Bullish Vectrus, Inc. (VEC)

Among 5 analysts covering Vectrus Inc (NYSE:VEC), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Vectrus Inc had 11 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by Drexel Hamilton on Thursday, May 11. Sidoti initiated Vectrus, Inc. (NYSE:VEC) rating on Tuesday, October 27. Sidoti has “Neutral” rating and $25.0 target. The stock has “Hold” rating by Noble Financial on Wednesday, March 7. The company was downgraded on Monday, March 5 by Drexel Hamilton. The firm earned “Buy” rating on Wednesday, March 16 by Sidoti. As per Thursday, March 1, the company rating was maintained by Stifel Nicolaus. The firm has “Hold” rating given on Tuesday, July 28 by BB&T Capital. Sidoti upgraded the stock to “Buy” rating in Friday, January 8 report. The firm has “Hold” rating given on Monday, January 8 by Stifel Nicolaus. See Vectrus, Inc. (NYSE:VEC) latest ratings:

07/03/2018 Broker: Noble Financial Old Rating: Buy New Rating: Hold Downgrade
05/03/2018 Broker: Drexel Hamilton Old Rating: Buy New Rating: Hold Downgrade
02/03/2018 Broker: Noble Financial Rating: Buy
01/03/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $39.0 Maintain
08/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $36.0 Maintain
21/11/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $37 Initiates Coverage On

Bridges Investment Management Inc increased Gilead Sciences Inc (GILD) stake by 34.9% reported in 2017Q3 SEC filing. Bridges Investment Management Inc acquired 20,445 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Bridges Investment Management Inc holds 79,020 shares with $6.40 million value, up from 58,575 last quarter. Gilead Sciences Inc now has $104.79B valuation. The stock increased 0.84% or $0.67 during the last trading session, reaching $79.99. About 6.72 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since March 8, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Vectrus, Inc. provides infrastructure asset management, logistics and supply chain management, and information technology and network communication services to the U.S. government worldwide. The company has market cap of $411.13 million. It offers infrastructure asset management services, such as civil engineering, infrastructure, operation and maintenance, security, warehouse management and distribution, ammunition management, air base maintenance and operation, communication, emergency, transportation, and life support services for U.S. It has a 18.37 P/E ratio. Army, Air Force, and Navy.

The stock decreased 0.08% or $0.03 during the last trading session, reaching $36.97. About 162,624 shares traded or 110.38% up from the average. Vectrus, Inc. (NYSE:VEC) has risen 23.72% since March 8, 2017 and is uptrending. It has outperformed by 7.02% the S&P500.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.86’s average target is 22.34% above currents $79.99 stock price. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, August 31 by Jefferies. Berenberg initiated the shares of GILD in report on Thursday, September 22 with “Buy” rating. Oppenheimer initiated Gilead Sciences, Inc. (NASDAQ:GILD) rating on Thursday, February 11. Oppenheimer has “Outperform” rating and $120 target. Vetr upgraded the stock to “Buy” rating in Monday, August 17 report. The firm earned “Buy” rating on Monday, June 12 by Jefferies. Citigroup downgraded the stock to “Neutral” rating in Wednesday, February 8 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Cowen & Co on Wednesday, October 18. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, November 2 report. The firm earned “Outperform” rating on Monday, October 3 by RBC Capital Markets. The firm has “Market Perform” rating given on Wednesday, February 7 by Leerink Swann.

Investors sentiment decreased to 0.8 in 2017 Q3. Its down 0.23, from 1.03 in 2017Q2. It dropped, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. 233,000 are held by Bp Public. Moreover, Seabridge Investment Llc has 0.36% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Flossbach Von Storch Ag accumulated 3,620 shares or 0% of the stock. Mutual Of Omaha Commercial Bank Wealth Management has invested 0.3% in Gilead Sciences, Inc. (NASDAQ:GILD). Walter And Keenan Fincl Consulting Mi Adv has 6,800 shares for 0.25% of their portfolio. Hsbc Public Limited Co accumulated 0.36% or 2.75 million shares. Solaris Asset Mngmt Ltd Liability Co owns 850 shares for 0.04% of their portfolio. Wealthtrust has invested 0% in Gilead Sciences, Inc. (NASDAQ:GILD). Kcm Inv Advsrs Limited Liability Co holds 0.05% or 9,717 shares. Segall Bryant & Hamill Limited Liability Corporation holds 20,478 shares or 0.04% of its portfolio. Howland Capital Ltd Company reported 256,501 shares stake. Windward Cap Management Ca invested 0.54% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Amer Natl Registered Advisor reported 10,301 shares. Fmr Limited Liability Company invested 0.27% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Sequoia Fincl Advisors Ltd stated it has 0.84% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD).